PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2992581-1 1985 The preferred average conformation and structural subdomain interactions of the nonapeptide hormones vasopressin and ocytocin have been analyzed through the determination of their hydrodynamic volume and the thermal coefficient of the frictional resistance to rotation of their tyrosine residue. Tyrosine 278-286 arginine vasopressin Homo sapiens 101-112 240713-7 1975 In the vasopressin series the stacking interaction of neighbouring aromatic amino acid residues furthermore limits the conformational freedom of the tyrosine side-chain and also probably distorts the dihedral angles of residues 1-3 in comparison with oxytocin. Tyrosine 149-157 arginine vasopressin Homo sapiens 7-18 7138841-3 1982 The binding of ocytocin, vasopressin, and the tripeptide analogue of the N-terminal sequence of ocytocin, Cys(S-Me)-Tyr-Ile-NH2, results in an increase of S020,W and a decrease in both the reduced viscosity and rotational relaxation time of the bis-liganded dimeric species vs. the nonliganded form. Tyrosine 116-119 arginine vasopressin Homo sapiens 25-36 839004-0 1977 Synthesis of specific deuterium labeled tyrosine and phenylalanine derivatives and their use in the total synthesis of [8-arginine]vasopressin derivatives: The separation of diastereomeric [8-arginine]vasopressin derivatives by partition chromatography1,2. Tyrosine 40-48 arginine vasopressin Homo sapiens 131-142 839004-0 1977 Synthesis of specific deuterium labeled tyrosine and phenylalanine derivatives and their use in the total synthesis of [8-arginine]vasopressin derivatives: The separation of diastereomeric [8-arginine]vasopressin derivatives by partition chromatography1,2. Tyrosine 40-48 arginine vasopressin Homo sapiens 201-212 1245474-6 1976 Polymerization observed with vasopressin was significantly greater than with oxytocin; for these peptides the tyrosine residues in the monomeric product were converted to 3-nitrotyrosine. Tyrosine 110-118 arginine vasopressin Homo sapiens 29-40 7418787-1 1980 Lysine vasopressin tritiated at meta position of tyrosine (1.9 Ci/mmole) decomposes during a long storage period, mainly as a result of radiolysis. Tyrosine 49-57 arginine vasopressin Homo sapiens 7-18 7392038-4 1980 This result of Nalpha-acetylation of Tyr(Me)AVP parallels similar results in the oxytocin series and suggests that this substitution should be considered in the design of potential antagonists of the antidiuretic response to vasopressin. Tyrosine 37-40 arginine vasopressin Homo sapiens 225-236 240713-9 1975 Consequently the local conformation of vasopressin in the region of the tyrosine residue is more rigid and less sensitive to changes in medium than that of oxytocin. Tyrosine 72-80 arginine vasopressin Homo sapiens 39-50 11168841-9 2001 Further evidence that intranuclear release of vasopressin and oxytocin is a prerequisite for cAMP stimulation of vasopressin and oxytocin release was obtained by demonstrating that d(CH2)5-D-Tyr(Me)VAVP, a potent combined V1a/V2/oxytocin receptor antagonist blocked stimulation of vasopressin and oxytocin release by 8-Br-cAMP. Tyrosine 190-194 arginine vasopressin Homo sapiens 46-57 16567810-4 2006 In the present study, we show for the first time that AVP stimulation of vascular smooth muscle cells (VSMCs) induces STAT3 tyrosine and serine phosphorylation, followed by nuclear translocation of the phosphorylated STAT3. Tyrosine 124-132 arginine vasopressin Homo sapiens 54-57 16567810-5 2006 In addition, we found that AVP induced JAK2 tyrosine phosphorylation. Tyrosine 44-52 arginine vasopressin Homo sapiens 27-30 16567810-7 2006 Furthermore, our results indicate that AVP-induced STAT3 tyrosine phosphorylation requires both JAK2 and c-Src tyrosine kinases. Tyrosine 57-65 arginine vasopressin Homo sapiens 39-42 16567810-9 2006 We further suggest that AVP-induced STAT3 serine phosphorylation negatively modulates AVP-induced STAT3 tyrosine phosphorylation. Tyrosine 104-112 arginine vasopressin Homo sapiens 24-27 16567810-9 2006 We further suggest that AVP-induced STAT3 serine phosphorylation negatively modulates AVP-induced STAT3 tyrosine phosphorylation. Tyrosine 104-112 arginine vasopressin Homo sapiens 86-89 13869528-5 1962 Analogues of oxytocin and vasopressin, in which tyrosine is replaced by phenylalanine, were not inactivated by the tyrosinase preparation used. Tyrosine 48-56 arginine vasopressin Homo sapiens 26-37 17803258-0 2007 Targeted tyrosine iodination in a multi-tyrosine vasopressin analog. Tyrosine 9-17 arginine vasopressin Homo sapiens 49-60 17803258-1 2007 Iodination of the conserved 2-tyrosine (Tyr(2)) residue in the pressin and tocin rings of arginine- or lysine-vasopressin (AVP or LVP), and oxytocin, respectively, impairs binding to their respective receptors. Tyrosine 40-43 arginine vasopressin Homo sapiens 110-121 17803258-8 2007 This fully reversible tyrosine protection strategy does not require special equipment, and retains the conserved Tyr(2), typical of vasopressin and oxytocin agonists. Tyrosine 22-30 arginine vasopressin Homo sapiens 132-143 16682840-6 2006 This mutation occurs at position 2 in AVP and predicts a substitution of serine for tyrosine (Y21S). Tyrosine 84-92 arginine vasopressin Homo sapiens 38-41 11168841-9 2001 Further evidence that intranuclear release of vasopressin and oxytocin is a prerequisite for cAMP stimulation of vasopressin and oxytocin release was obtained by demonstrating that d(CH2)5-D-Tyr(Me)VAVP, a potent combined V1a/V2/oxytocin receptor antagonist blocked stimulation of vasopressin and oxytocin release by 8-Br-cAMP. Tyrosine 190-194 arginine vasopressin Homo sapiens 113-124 11168841-9 2001 Further evidence that intranuclear release of vasopressin and oxytocin is a prerequisite for cAMP stimulation of vasopressin and oxytocin release was obtained by demonstrating that d(CH2)5-D-Tyr(Me)VAVP, a potent combined V1a/V2/oxytocin receptor antagonist blocked stimulation of vasopressin and oxytocin release by 8-Br-cAMP. Tyrosine 190-194 arginine vasopressin Homo sapiens 113-124 8060340-6 1994 A third interaction is between a conserved tyrosine and the glutamine of vasopressin and oxytocin. Tyrosine 43-51 arginine vasopressin Homo sapiens 73-84 9888517-0 1998 Involvement of tyrosine phosphorylation and MAPK activation in the mechanism of action of ACTH, angiotensin II and vasopressin. Tyrosine 15-23 arginine vasopressin Homo sapiens 115-126 8852563-6 1996 However, the width of the distance distribution is narrower for vasopression (hw = 2.80 A) than for oxytocin (hw = 3.58 A), which is consistent with restriction of the tyrosine phenol motion due to its stacking wih the Phe3 side chain of vasopressin. Tyrosine 168-176 arginine vasopressin Homo sapiens 238-249 8871886-4 1996 The V1a receptor antagonist [d(CH2)5(1), Tyr(Me)2, Arg8]-vasopressin inhibited the AVP-(IC50, 5 x 10(-9) mol/l) and oxytocin-induced (IC50, 3 x 10(-8) mol/l) increase in [Ca2+]i in a dose-dependent manner. Tyrosine 41-44 arginine vasopressin Homo sapiens 57-68 8871886-4 1996 The V1a receptor antagonist [d(CH2)5(1), Tyr(Me)2, Arg8]-vasopressin inhibited the AVP-(IC50, 5 x 10(-9) mol/l) and oxytocin-induced (IC50, 3 x 10(-8) mol/l) increase in [Ca2+]i in a dose-dependent manner. Tyrosine 41-44 arginine vasopressin Homo sapiens 83-86 7532010-3 1995 Here we show that almost identical patterns of phosphotyrosine-containing proteins are detectable in the cytoskeleton after platelet stimulation with compounds that directly (phorbol 12-myristate, 13-acetate) or indirectly (thrombin, vasopressin, collagen, ADP) activate protein kinase C. The apparent molecular masses of the proteins phosphorylated at tyrosine residues are 145, 130, 100, 85, 80, 60, 56, 54 and 38 kDa. Tyrosine 54-62 arginine vasopressin Homo sapiens 234-245 7532010-6 1995 The time course of protein tyrosine phosphorylation for thrombin- and vasopressin-stimulated platelets revealed a rapid increase in the cytoskeleton within 5 to 20 s following activation consistent with a role in early events of platelet function. Tyrosine 27-35 arginine vasopressin Homo sapiens 70-81 7802081-13 1994 The analog 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin, which blocks both the oxytocin and the V1 vasopressin receptor, should inhibit labor both preterm and at term, the former confirming results of recent clinical studies in Sweden and the United States. Tyrosine 25-28 arginine vasopressin Homo sapiens 98-109 24242994-0 1991 Conformational differences of oxytocin and vasopressin as observed by fluorescence anisotropy decays and transient effects in collisional quenching of tyrosine fluorescence. Tyrosine 151-159 arginine vasopressin Homo sapiens 43-54 1995653-5 1991 The other two probably recognize tyrosine containing epitope(s) also shared by vasopressin and other related nonapeptides. Tyrosine 33-41 arginine vasopressin Homo sapiens 79-90 2145088-5 1990 Vasopressin constricted guinea pig and human submucosal arterioles (EC50, 1 nM) by activating classical V1 receptors; dissociation equilibrium constants (Kd) for the V1 antagonist d(CH2)5 Tyr (Me) arginine vasopressin were 1-3 nM. Tyrosine 188-191 arginine vasopressin Homo sapiens 0-11 1692212-0 1990 Vasopressin dependent tyrosine phosphorylation of a 38 kDa protein in human platelets. Tyrosine 22-30 arginine vasopressin Homo sapiens 0-11 1692212-7 1990 These observations suggest that arginine vasopressin signal transduction may be associated with the tyrosine phosphorylation of a 38 kDa protein. Tyrosine 100-108 arginine vasopressin Homo sapiens 41-52 8238319-0 1993 AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Arginine vasopressin (AVP) has been shown to stimulate tyrosine phosphorylation and activation of p42 mitogen-activated protein (MAP) kinase (p42MAPK) in vascular smooth muscle cells (VSMC). Tyrosine 162-170 arginine vasopressin Homo sapiens 0-3 8238319-0 1993 AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Arginine vasopressin (AVP) has been shown to stimulate tyrosine phosphorylation and activation of p42 mitogen-activated protein (MAP) kinase (p42MAPK) in vascular smooth muscle cells (VSMC). Tyrosine 162-170 arginine vasopressin Homo sapiens 129-132 8197874-1 1993 Solid-phase synthesis methods were applied to prepare some arginine vasopressin (AVP) analogues containing L- or D-pipecolic acids or alpha-L-homoproline in position 7, D-Cys in position 6, D-Val in position 4, O-alkylated D- or L-Tyr in position 2 and Pmp [1-(beta-mercapto-beta, beta-cyclopentamethylidenepropionic acid)] in position 1. Tyrosine 229-234 arginine vasopressin Homo sapiens 68-79